vs
Prime Medicine, Inc.（PRME）与Roivant Sciences Ltd.（ROIV）财务数据对比。点击上方公司名可切换其他公司
Roivant Sciences Ltd.的季度营收约是Prime Medicine, Inc.的2.4倍（$2.0M vs $838.0K），Prime Medicine, Inc.净利率更高（-5498.7% vs -13301.2%，领先7802.5%），Prime Medicine, Inc.同比增速更快（-61.6% vs -77.8%），Prime Medicine, Inc.自由现金流更多（$-37.5M vs $-201.4M）
Prime Medicine, Inc.是一家总部位于美国马萨诸塞州剑桥的生物科技企业，核心业务是依托先导编辑技术开发新型基因治疗方案，致力于为遗传病等相关疾病探索创新治疗手段，推动前沿基因编辑技术的临床转化与应用。
Roivant Sciences Ltd.是一家美国跨国医疗健康企业，2014年由维韦克·拉马斯瓦米创立，现任CEO为马特·格林。公司专注于将技术应用于药物研发领域，同时孵化运营多家生命科学与健康科技子公司，总部位于纽约，在波士顿、巴塞尔两大生物科技产业集群也设有核心办公点。
PRME vs ROIV — 直观对比
营收规模更大
ROIV
是对方的2.4倍
$838.0K
营收增速更快
PRME
高出16.2%
-77.8%
净利率更高
PRME
高出7802.5%
-13301.2%
自由现金流更多
PRME
多$163.9M
$-201.4M
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $838.0K | $2.0M |
| 净利润 | $-46.1M | $-265.9M |
| 毛利率 | — | — |
| 营业利润率 | -5800.5% | -16966.1% |
| 净利率 | -5498.7% | -13301.2% |
| 营收同比 | -61.6% | -77.8% |
| 净利润同比 | -9.0% | -257.0% |
| 每股收益（稀释后） | $-0.22 | $-0.38 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PRMEROIV
| Q4 25 | $838.0K | $2.0M | ||
| Q3 25 | $1.2M | $1.6M | ||
| Q2 25 | $1.1M | $2.2M | ||
| Q1 25 | $1.5M | $-39.6M | ||
| Q4 24 | $2.2M | $9.0M | ||
| Q3 24 | — | $4.5M | ||
| Q2 24 | $0 | $8.0M | ||
| Q1 24 | $591.0K | $28.9M |
净利润PRMEROIV
| Q4 25 | $-46.1M | $-265.9M | ||
| Q3 25 | $-50.6M | $-113.5M | ||
| Q2 25 | $-52.6M | $-223.4M | ||
| Q1 25 | $-51.9M | $-206.5M | ||
| Q4 24 | $-42.3M | $169.4M | ||
| Q3 24 | — | $-230.2M | ||
| Q2 24 | $-55.3M | $95.3M | ||
| Q1 24 | $-45.8M | $-151.1M |
营业利润率PRMEROIV
| Q4 25 | -5800.5% | -16966.1% | ||
| Q3 25 | -4406.0% | -19492.9% | ||
| Q2 25 | -4787.2% | -13130.0% | ||
| Q1 25 | -3603.3% | 674.8% | ||
| Q4 24 | -2025.7% | -3042.6% | ||
| Q3 24 | — | -7636.0% | ||
| Q2 24 | — | -1279.5% | ||
| Q1 24 | -8179.5% | -919.5% |
净利率PRMEROIV
| Q4 25 | -5498.7% | -13301.2% | ||
| Q3 25 | -4129.1% | -7225.9% | ||
| Q2 25 | -4716.7% | -10292.9% | ||
| Q1 25 | -3568.8% | 521.8% | ||
| Q4 24 | -1936.6% | 1878.3% | ||
| Q3 24 | — | -5143.8% | ||
| Q2 24 | — | 1192.7% | ||
| Q1 24 | -7743.0% | -522.3% |
每股收益（稀释后）PRMEROIV
| Q4 25 | $-0.22 | $-0.38 | ||
| Q3 25 | $-0.32 | $-0.17 | ||
| Q2 25 | $-0.41 | $-0.33 | ||
| Q1 25 | $-0.40 | $-0.28 | ||
| Q4 24 | $-0.31 | $0.23 | ||
| Q3 24 | — | $-0.31 | ||
| Q2 24 | $-0.46 | $0.12 | ||
| Q1 24 | $-0.44 | $-0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $63.0M | $4.5B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $120.9M | $4.3B |
| 总资产 | $342.7M | $5.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PRMEROIV
| Q4 25 | $63.0M | $4.5B | ||
| Q3 25 | $71.4M | $4.4B | ||
| Q2 25 | $53.8M | $4.5B | ||
| Q1 25 | $91.9M | $4.9B | ||
| Q4 24 | $182.5M | $5.1B | ||
| Q3 24 | — | $5.4B | ||
| Q2 24 | $55.6M | $5.7B | ||
| Q1 24 | $94.2M | $6.5B |
总债务PRMEROIV
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $311.7M | ||
| Q1 24 | — | $430.6M |
股东权益PRMEROIV
| Q4 25 | $120.9M | $4.3B | ||
| Q3 25 | $161.8M | $4.4B | ||
| Q2 25 | $60.9M | $4.3B | ||
| Q1 25 | $106.9M | $4.7B | ||
| Q4 24 | $153.1M | $5.2B | ||
| Q3 24 | — | $5.2B | ||
| Q2 24 | $196.6M | $5.4B | ||
| Q1 24 | $243.8M | $6.0B |
总资产PRMEROIV
| Q4 25 | $342.7M | $5.2B | ||
| Q3 25 | $385.0M | $5.1B | ||
| Q2 25 | $279.0M | $5.0B | ||
| Q1 25 | $328.2M | $5.4B | ||
| Q4 24 | $297.5M | $5.8B | ||
| Q3 24 | — | $6.2B | ||
| Q2 24 | $259.7M | $6.5B | ||
| Q1 24 | $311.4M | $7.2B |
负债/权益比PRMEROIV
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.06× | ||
| Q1 24 | — | 0.07× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-37.3M | $-196.5M |
| 自由现金流经营现金流 - 资本支出 | $-37.5M | $-201.4M |
| 自由现金流率自由现金流/营收 | -4480.4% | -10076.0% |
| 资本支出强度资本支出/营收 | 34.6% | 246.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-167.1M | $-776.7M |
8季度趋势，按日历期对齐
经营现金流PRMEROIV
| Q4 25 | $-37.3M | $-196.5M | ||
| Q3 25 | $-35.0M | $-185.7M | ||
| Q2 25 | $-41.4M | $-204.4M | ||
| Q1 25 | $-48.9M | $-172.6M | ||
| Q4 24 | $16.2M | $-207.3M | ||
| Q3 24 | — | $-266.8M | ||
| Q2 24 | $-45.5M | $-192.8M | ||
| Q1 24 | $-67.7M | $-108.5M |
自由现金流PRMEROIV
| Q4 25 | $-37.5M | $-201.4M | ||
| Q3 25 | $-35.3M | $-193.5M | ||
| Q2 25 | $-43.0M | $-208.4M | ||
| Q1 25 | $-51.3M | $-173.4M | ||
| Q4 24 | $14.5M | $-209.1M | ||
| Q3 24 | — | $-267.8M | ||
| Q2 24 | $-47.4M | $-193.8M | ||
| Q1 24 | $-70.0M | $-108.8M |
自由现金流率PRMEROIV
| Q4 25 | -4480.4% | -10076.0% | ||
| Q3 25 | -2880.5% | -12317.8% | ||
| Q2 25 | -3855.1% | -9604.5% | ||
| Q1 25 | -3526.8% | 438.1% | ||
| Q4 24 | 662.1% | -2318.5% | ||
| Q3 24 | — | -5984.4% | ||
| Q2 24 | — | -2425.5% | ||
| Q1 24 | -11849.6% | -376.1% |
资本支出强度PRMEROIV
| Q4 25 | 34.6% | 246.9% | ||
| Q3 25 | 20.2% | 499.6% | ||
| Q2 25 | 141.0% | 185.9% | ||
| Q1 25 | 166.6% | -2.0% | ||
| Q4 24 | 82.0% | 20.3% | ||
| Q3 24 | — | 22.3% | ||
| Q2 24 | — | 12.1% | ||
| Q1 24 | 393.2% | 1.2% |
现金转化率PRMEROIV
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -1.22× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -2.02× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
